聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎的临床观察.pdf

《聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎的临床观察.pdf》由会员上传分享，免费在线阅读，更多相关内容在应用文档-天天文库。

1、昆明医科大学学报2014，35(2)：100—101CN53—1221／RJournalofKunmingMedicalUniversity聚乙二醇干扰素()c一2a联合利巴韦林治疗慢性丙型肝炎的临床观察杨永锐”，李晖”，沈凌(1)昆明市第三人民医院，云南昆明650041；2)昆明医科大学公共卫生学院，云南昆明650500)[摘要]目的观察聚乙二醇干扰素一2a联合利巴韦林治疗慢性丙型肝炎的疗效和安全性．方法将106例慢性丙型肝炎患者随机分为2组，给予抗病毒治疗，实验组给予皮下注射聚乙二醇干扰素一2a180，每周1次；对照组给予皮下注射干扰素一lb5MIU，隔日1次，2组均按体重同时服用联合利巴

2、韦林900～1200rag，每天1次，疗程48周．分别在治疗前、治疗第4周、l2周、24周、治疗结束时、治疗结束后24周测定患者血清HCV—RNA水平，同时观察不良反应．结果实验组的快速病毒学应答率(RVR)为77．4％，完全早期病毒学应答率(cEVR)为83．0％，治疗结束应答率(ETVR)为90．6％，治疗结束后随访24周持续应答率(SVR)为84．9％，明显优于对照组．结论聚乙二醇干扰素一2a联合利巴韦林治疗慢性丙型肝炎具有良好的抗病毒疗效，安全性较好．[关键词]慢性丙型肝炎；聚乙二醇干扰素t一2a；利巴韦林；疗效；安全性[中图分类号]R512．6[文献标识码]A[文章编号]2095-6

3、10X(2014)02—010o一03ClinicalObservationofChronicHepatitisCTreatedby-PegylatedInterferonAlpha-2aPlusRibavirinYANGYong-rui”，LIHui”，SHENLing2】(1)Dept．ofHepatology，The3rdPeople’sHospitalofKunming，KunmingYunnan650041；2)SchoolofPublicHealth，KunmingMedicalUniversity，KunmingYunnan650500，China)[Abstract]Objec

4、tiveToobservetheeficacyandsafetyofpegylatedinterferonapha-2acombinedwithribavirininthetreatmentofchronichepatitisC．MethodsOnehundredandsixpatientswithchronichepatitisCweredividedinto2groupsrandomly．Patientsintheobservationgroupweretreatedwithpegylatedinterferonalpha-2a，andpatientsinthecontrolgroupwe

5、retreatedwithinterferonalpha-lb．Allpatientsweregivenribavirinaccordingtotheweight，andthetreatmentcoursewas48weeks．HCV—RNAwastestedbeforetreatment，4weeks，12weeksand24weeksafterthestartoftreatment，endoftreatment，24weeksaftertheendoftreatment．Theadversereactionswerealsoobserved．ResultsIntheobservationg

6、roup，therapidvirologicalresponse(RVR)was77．4％，thecompleteearlyvirologicalresponse(cEVR)was83．0％，theendtreatmentvirologicalresponse(ETVR)was90．6％，thesustainedvirologicalresponse(SVR)of24weeksaftertheendoftreatmentwas84．9％．andtheseratesweresignificantlyhigherthanthecontrolgroup．Allpatientsreceivedthew

7、holecourseoftreatment．CondusionTreatmentofchronichepatitisCwithpegylatedinterferonapha一2acombinedwithribaviriniseffectiveandsafe．[Keywords]ChronichepatitisC；Pegylatedinterferonalpha-2a；Ribavirin；Efica